ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Induction therapy"

  • 2018 American Transplant Congress

    Deceased Donor Urinary Biomarker Signature and the Effectiveness of Peritransplant Lymphocyte Depletion on Early Renal Allograft Function

    S. Bernd,2 P. Heeger,1 T-.P. Heather,3 I. Hall,7 M. Doshi,4 F. Weng,5 P. Reese,6 C. Parikh.3

    1Icahn School of Medicine Mount Sinai, New York, NY; 2University of Ulm, Ulm, Germany; 3Yale University School of Medicine, New Haven, CT; 4Wayne State University, Detroit, MI; 5Barnabas Health, Livingston, NJ; 6University of Pennsylvania, Philadelphia, PA; 7University of Utah School of Medicine, Salt Lake City, UT.

    Purpose: Delayed graft function (DGF) is associated with increased allogaft immunogenicity and decreased long-term survival. We hypothesized that high levels of donor urinary biomarkers for…
  • 2018 American Transplant Congress

    Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression

    J. Benken,1 C. Kane,2 A. Lichvar,1 E. Benedetti.1

    1University of Illinois at Chicago, Chicago, IL; 2University of Northwestern Memorial Hospital, Chicago, IL.

    Introduction: Basilixiab is a fixed-dose IL-2 receptor antagonist that is used for non-lymphodepleting induction therapy. The impact of obesity on basiliximab pharmacokinetics and pharmacodynamics is…
  • 2018 American Transplant Congress

    Single Reduced Dose Thymoglobuline as Induction in Kidney Retransplant

    K. Linhares-Silva, M. Cristelli, L. Viana, C. Felipe, H. Proença, R. de Marco, J. Medina-Pestana, H. Tedesco Silva J�nior.

    Hospital do Rim, São Paulo, Brazil.

    IntroductionKidney retransplant is a high risk procedure, without a consensus about the best induction imunnossupression strategy. Only a few studies have evaluated these growing proportion…
  • 2018 American Transplant Congress

    Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort

    J. Schulte,1 C. Richardson,1 V. Stosor,2 K. Cunningham,1 C. D'Agostino,1 C. Kane.1

    1Pharmacy, Northwestern Memorial Hospital, Chicago; 2Infectious Diseases and Organ Transplantation, Northwestern Memorial Hospital, Chicago.

    Purpose: There is an elevated risk of acute rejection in HIV+ renal transplant recipients and continued evaluation of the most appropriate induction therapy remains. Use…
  • 2018 American Transplant Congress

    A Meta-Analysis for Induction Therapy of Kidney Transplantation: Comparison of Antithymocyte Globulin and Interleukin 2 Receptor Antagonist

    G. Chen, Z. Wu, C. Wang, X. Liu, C. Wang, L. Chen.

    Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

    Objectives To compare the efficacy and safety of antithymocyte globulin (ATG) and interleukin 2 receptor antagonist (IL2Ra) in induction therapy of kidney transplantation.Method A literature…
  • 2018 American Transplant Congress

    Improved Value with Individualized Antithymocyte Globulin Dosing Protocol in Renal Transplant

    J. Dann, W. Ally, M. Bradley, J. Geyston, A. Agarwal.

    University of Virginia Healthsystem, Charlottesville, VA.

    Medication costs represent one of the largest costs associated with transplantation. With growing pressure to reduce health care costs while maintaining excellent outcomes, this study…
  • 2017 American Transplant Congress

    BK Polyoma Virus and Malignancy: Cause or Co-Incidence?

    R. Prashar, A. Shah, D. Stewart, S. Williamson, A. Patel.

    Henry Ford Transplant Institute, Detroit, MI

    BackgroundThe WHO agency for cancer research has classified BKV as "possibly carcinogenic".The etiological role of BKV in human cancer, however,remains controversial.We present 5 cases of…
  • 2017 American Transplant Congress

    Three Induction Therapies on Patients with Delayed Graft Function After Kidney Transplantation, a Three-Year Outcome Analysis.

    A. Umber, M. Killackey, A. Paramesh, B. Alper, F. Teran, A. Baudy, Y. Liu, J. Buell, R. Zhang.

    Departments of Medicine and Surgery, Tulane University School of Medicine, New Orleans, LA

    We compare the 3-year outcomes of induction therapies with either methylprednisolone (group 1, n=58), basiliximab (group 2, n=56) or alemtuzumab (group 3, n=98) in primary…
  • 2017 American Transplant Congress

    The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.

    J. Husson, R. Adekunle, B. Ravichandran, P. Mathur, S. Jonchhe, K. Stafford.

    University of Maryland Medical Center, Baltimore, MD

    Background: Renal transplant recipients (RTRs) with HCV are at an increased risk of graft rejection, making treatment of HCV in this population of the utmost…
  • 2017 American Transplant Congress

    Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).

    B. Burrell,1 J. Bromberg,2 C. Hartono,3 A. Posselt,4 A. Naji,5 D. Kaufman,6 R. Redfield III,6 S. Kanaparthi,1 D. Ikle,7 K. Much,7 N. Bridges,8 L. Sun,1 A. Priore,8 M. DesMarais,1 K. Crisalli,9 S. Chandran,1 J. Markmann.9

    1ITN, Bethesda/San Francisco; 2UMD, Baltimore; 3Rogosin, New York; 4UCSF, San Francisco; 5UPenn, Philadelphia; 6UWisconsin, Madison; 7Rho, Chapel Hill; 8NIAID/NIH, Bethesda; 9MGH, Boston

    Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 31
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences